Global Variations in Heart Failure Etiology, Management, and Outcomes

Data de publicação: 16/05/2023

Autores da FMUP

José Carlos De Magalhães Silva Cardoso

Autor

Participantes de fora da FMUP

Joseph, P
Roy, A
Lonn, E
Störk, S
Floras, J
Mielniczuk, L
Rouleau, JL
Zhu, J
Dzudie, A
Balasubramanian, K
Karaye, K
AlHabib, KF
Gómez-Mesa, JE
Branch, KR
Makubi, A
Budaj, A
Avezum, A
Wittlinger, T
Ertl, G
Mondo, C
Pogosova, N
Maggioni, AP
Orlandini, A
Parkhomenko, A
ElSayed, A
López-Jaramillo, P
Grinvalds, A
Temizhan, A
Hage, C
Lund, LH
Kazmi, K
Lanas, F
Sharma, SK
Fox, K
McMurray, JJV
Leong, D
Dokainish, H
Khetan, A
Yonga, G
Kragholm, K
Shaker, KW
Mwita, JC
Al Mulla, AA
Alla, F
Damasceno, A
Dans, AL
Sliwa, K
O'Donnell, M
Bazargani, N
Bayés-Genís, A
McCready, T
Probstfield, J
Yusuf, S
G-CHF Investigators

Unidades de investigação

Laboratório Associado RISE- Rede de Investigação em Saúde

Investigador

Fernando Carlos De Landér Schmitt
Medicina
RISE-Health

Investigador

Fernando Carlos De Landér Schmitt

Abstract

Importance Most epidemiological studies of heart failure (HF) have been conducted in high-income countries with limited comparable data from middle- or low-income countries. Objective To examine differences in HF etiology, treatment, and outcomes between groups of countries at different levels of economic development. Design, Setting, and Participants Multinational HF registry of 23341 participants in 40 high-income, upper-middle-income, lower-middle-income, and low-income countries, followed up for a median period of 2.0 years. Main Outcomes and Measures HF cause, HF medication use, hospitalization, and death. Results Mean (SD) age of participants was 63.1 (14.9) years, and 9119 (39.1%) were female. The most common cause of HF was ischemic heart disease (38.1%) followed by hypertension (20.2%). The proportion of participants with HF with reduced ejection fraction taking the combination of a beta-blocker, renin-angiotensin system inhibitor, and mineralocorticoid receptor antagonist was highest in upper-middle-income (61.9%) and high-income countries (51.1%), and it was lowest in low-income (45.7%) and lower-middle-income countries (39.5%) (P<.001). The age- and sex- standardized mortality rate per 100 person-years was lowest in high-income countries (7.8 [95% CI, 7.5-8.2]), 9.3 (95% CI, 8.8-9.9) in upper-middle-income countries, 15.7 (95% CI, 15.0-16.4) in lower-middle-income countries, and it was highest in low-income countries (19.1 [95% CI, 17.6-20.7]). Hospitalization rates were more frequent than death rates in high-income countries (ratio=3.8) and in upper-middle-income countries (ratio=2.4), similar in lower-middle-income countries (ratio=1.1), and less frequent in low-income countries (ratio=0.6). The 30-day case-fatality rate after first hospital admission was lowest in high-income countries (6.7%), followed by upper-middle-income countries (9.7%), then lower-middle-income countries (21.1%), and highest in low-income countries (31.6%). The proportional risk of death within 30 days of a first hospital admission was 3- to 5-fold higher in lower-middle-income countries and low-income countries compared with high-income countries after adjusting for patient characteristics and use of long-term HF therapies. Conclusions and Relevance This study of HF patients from 40 different countries and derived from 4 different economic levels demonstrated differences in HF etiologies, management, and outcomes. These data may be useful in planning approaches to improve HF prevention and treatment globally.

Dados da publicação

ISSN/ISSNe:: 1538-3598, 0098-7484
Tipo:: Article
Páginas:: 1650-1661
DOI:: 10.1001/jama.2023.5942
Link para outro recurso:: www.scopus.com

Documentos

Não há documentos

Métricas

Filiações

Keywords

INITIATE LIFESAVING TREATMENT; HEALTH-CARE UTILIZATION; HOSPITALIZED-PATIENTS; PREDICTING SURVIVAL; ORGANIZED PROGRAM; CARDIAC-SURGERY; RISK SCORE; REGISTRY; HF; MORTALITY

Campos de estudo